Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) – B. Riley raised their Q2 2019 earnings per share estimates for Cumberland Pharmaceuticals in a research note issued on Wednesday, May 15th. B. Riley analyst A. D’silva now expects that the specialty pharmaceutical company will post earnings per share of $0.07 for the quarter, up from their prior estimate of ($0.03). B. Riley also issued estimates for Cumberland Pharmaceuticals’ Q3 2019 earnings at $0.12 EPS, Q4 2019 earnings at $0.06 EPS, FY2019 earnings at $0.37 EPS, FY2020 earnings at $0.46 EPS and FY2021 earnings at $0.99 EPS.
Several other analysts have also recently weighed in on CPIX. TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, April 10th. Zacks Investment Research downgraded shares of Cumberland Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 6th.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.24. The business had revenue of $13.50 million during the quarter, compared to analyst estimates of $10.98 million. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.51%.
Several hedge funds and other institutional investors have recently bought and sold shares of CPIX. Renaissance Technologies LLC raised its stake in Cumberland Pharmaceuticals by 2.5% in the 1st quarter. Renaissance Technologies LLC now owns 390,777 shares of the specialty pharmaceutical company’s stock worth $2,270,000 after purchasing an additional 9,403 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in Cumberland Pharmaceuticals in the 1st quarter valued at about $63,000. Finally, Stonepine Capital Management LLC grew its holdings in shares of Cumberland Pharmaceuticals by 7.8% during the 4th quarter. Stonepine Capital Management LLC now owns 1,313,429 shares of the specialty pharmaceutical company’s stock valued at $7,920,000 after purchasing an additional 95,028 shares during the last quarter. Institutional investors own 32.22% of the company’s stock.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.